<DOC>
	<DOCNO>NCT02965859</DOCNO>
	<brief_summary>The study objective evaluate safety effectiveness different dos Metacavir Enteric-coated Capsules treatment chronic hepatitis B , well find appropriate clinical dosage compare effect different dos treatment , order provide reference clinical trial next phase .</brief_summary>
	<brief_title>The Safety Dose-range Study Metacavir Enteric-coated Capsules Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>180 eligible subject included.According set group method dose escalation.Subjects randomize 1:1:1:1 proportion Metacavir Enteric-coated Capsules ( 80mg/160mg/320mg ) group , positive control group placebo control group.Each group 36 subject . 1.Subjects use study medication ( 2 hour meal , day ) Visit 3 Visit 5 . 1 . Metacavir Enteric-coated Capsules 80mg Group : Metacavir Enteric-coated Capsules 80mg , Metacavir Enteric-coated Capsules Placebo 240mg , Adefovir Dipivoxil Capsule Placebo 10mg ; 2 . Metacavir Enteric-coated Capsules 160mg Group : Metacavir Enteric-coated Capsules 160mg , Metacavir Enteric-coated Capsules Placebo 160mg , Adefovir Dipivoxil Capsule Placebo 10mg ; 3 . Metacavir Enteric-coated Capsules 320mg Group : Metacavir Enteric-coated Capsules 320mg , Adefovir Dipivoxil Capsule Placebo 10mg ; 4 . Positive Control ( Adefovir Dipivoxil Capsule ) Group : Metacavir Enteric-coated Capsules Placebo 320mg , Adefovir Dipivoxil Capsule 10mg ; 5 . Placebo Control Group : Metacavir Enteric-coated Capsules Placebo 320mg , Adefovir Dipivoxil Capsule Placebo 10mg ;</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Are least 18 year age old 65 ; Subjects , establish clinical history HBV Screening , positive HBsAg test ( &gt; 6months ) regardless positive/negative HBeAg test ; At Screening , HBVDNA &gt; 10^5 copies/ml HBeAg positive HBVDNA &gt; 10^4 copies/ml HBeAg negative ( HBVDNA evaluate polymerase chain reaction fluorescent label . ) ; Subjects abnormal liver function test define alanine aminotransferase ( ALT ) 2~10 time upper limit normal HBeAg positive 1.5~10 time upper limit normal HBeAg negative ; Subjects willing require treatment antihepatitis B study period ; Subjects willing take measure effective nonpharmaceutical contraception ; Given sign write informed consent participate ; Subjects hepatitis C ( HCV ) , hepatitis D ( HDV ) , autoimmune hepatitis , hereditary liver disease active hepatitis ; A positive human immunodeficiency virus ( HIV ) test result ; Subjects , opinion investigator , current diagnosis hepatocellular carcinoma serum αfetoprotein ( AFP ) &gt; 100ug/L ; Subjects severe hepatitis decompensated liver disease define hepatic encephalopathy , ascites , low protein blood syndrome ( albumin ≤30g/l ) variceal bleeding ; Serum Creatinine ( SCr ) exceed upper limit normal ; At Screening , ALT &gt; 10 time upper limit normal , Total Bilirubin ( TBIL ) &gt; double upper limit normal transient hepatic decompensation cause condition aggravation ; Subjects require treatment nucleoside antiviral drug lamivudine , Adefovir dipivoxil , Telbivudine , Tenofovir disoproxil Entecavir Screening ; Subjects require treatment interferonα，thymosin α1 antiviral therapy , immunosuppressive agent , immune modulators within 6 month Screening ; Subjects cardiac disease , hematological system disease , cancer , impaired immunity psychiatric disease ; Hemoglobin &lt; 10g/dl , white blood cell count &lt; 3.5 10^9/L , platelet &lt; 80 10^9/L ; Subjects , opinion investigator , current diagnosis pancreatitis predose within 24 week ; History hypersensitivity allergy study drug ; Subjects participate clinical trial within 3 month prior Screening ; Women pregnant lactate planning pregnancy recently ; Subjects opinion investigator , could participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>